Auto-antibodies to anti-ENA SSA/RO (52 and 60 kDa): An auto-immunity laboratory's experience;Détection des anti-ENA anti-SSA (52 et 60 kDa): Expérience d'un laboratoire d'auto-immunité

Revue de Medecine Interne

Volumn 25, Issue 6, 2004, Pages 421-428

  Bahon Riedinger, I ^a  

^a PONTCHAILLOU UNIVERSITY HOSPITAL   (France)

Author keywords

Anti SSA 52 kD; Anti SSA 60 kD; Anti SSA Ro 52kD; Anti SSA Ro 60kD; Anti SSB; Anti SSB La; Autoantibodies; Autoanticorps; Connective Tissue Diseases; Connectivites

Indexed keywords

ANTIBODY; LA ANTIBODY; RO ANTIBODY; UNCLASSIFIED DRUG;

ARTICLE; AUTOIMMUNE DISEASE; AUTOIMMUNITY; CONNECTIVE TISSUE DISEASE; CONTROLLED STUDY; DOT HYBRIDIZATION; ENZYME LINKED IMMUNOSORBENT ASSAY; HOSPITAL SERVICE; HUMAN; IMMUNOLOGICAL PROCEDURES; MAJOR CLINICAL STUDY; MOLECULAR WEIGHT; SCREENING TEST; SERUM; SYSTEMIC LUPUS ERYTHEMATOSUS;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, ANTINUCLEAR; CHILD, PRESCHOOL; FEMALE; HUMANS; LUPUS; MALE; MIDDLE AGED; MOLECULAR WEIGHT; RIBONUCLEOPROTEINS; SJOGREN'S SYNDROME;

EID: 2542478252     PISSN: 02488663     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.revmed.2003.11.009     Document Type: Article

References (64)

1. Maisonneuve P., Burg E., Guyard A., Albarede S. Rapport du Contrôle national de qualité auto-immunité 00ATI1 AFSSAPS. 2000
2. Van Venrooij W.J., Charles P., Maini R.N. The consensus workshops for the detection of autoantibodies to intracellular antigens in rheumatic diseases. J Immunol Methods. 140:1991;181-189
3. Morozzi G., Bellisai F., Simpatico A., Pucci G., Bacarelli M.R., Campanella V., et al. Comparison of different methods for the detection of anti-Ro/SSA antibodies in connective tissue diseases. Clin Exp Rheumatol. 18:2000;729-731
4. Tan E.M., Smolen J.S., Mcdougal J.S., Butcher B.T., Conn D., Dawkins R., et al. A critical evaluation of enzyme immunoassays for detection of antinuclear autoantibodies of defined specificities. Arthritis Rheum. 42:1999;455-464
5. Meheus L., Van Venrooij W.J., Wiik A., Charles P.J., Tzioufas A.G., Meyer O., et al. Multicenter validation of recombinant, natural and synthetic antigens used in a single multiparameter assay for the detection of specific antinuclear autoantibodies in connective tissue disorders. Clin Exp Rheumatol. 17:1999;205-214
6. Lock R.J., Unsworth D. Antibodies to extractable nuclear antigens. Has technological drift affected clinical interpretation? J Clin Pathol. 54:2001;187-190
7. Peene I., Meheus L., Veys E.M., De Keyser F. Detection and identification of antinuclear antibodies (ANA) in a large and consecutive cohort of serum samples referred for ANA testing. Ann Rheum Dis. 69:2001;1131-1136
8. Ben-Chetrit E. The molecular basis of the SSA/Ro antigens and the clinical significance of their autoantibodies. Br J Rheumatol. 32:1993;396-402
9. Reichlin M., Scofield R.H. SSA/Ro autoantibodies, Peter and Shoenfeld Autoantibodies. 1996;783-789 Elsevier, Amsterdam
10. Von Muhlen C.A., Tan E.M. Autoantibodies in the diagnosis of systemic rheumatic diseases. Semin Arthritis Rheum. 24:1995;323-358
11. Youinou P., Adler Y., Muller S., Lamour A., Baron D., Humbel R.L. Anti-Ro(SSA) and Anti-La(SSB) antibodies in autoimmune rheumatic diseases. Clin Rev Allergy. 12:1994;253-274
12. Tishler M., Golbrut B., Shoenfeld Y., Yaron M. Anti-Ro(SSA) antibodies in patients with rheumatoid arthritis- a possible marker for gold induced side effects. J Rheumatol. 21:1994;1040-1042
13. Moutsopoulos H.M., Skopouli F.N., Sarras A.K., Tsampoulas C., Mavridis A.K., Constantopoulos S.H., et al. Anti-Ro(SSA) positive rheumatoid arthritis (RA): a clinicoserological group of patients with high incidence of D-penicillamine side effects. Ann Rheum Dis. 44:1985;215-219
14. Boire G., Menard H.A. Clinical significance of Anti-Ro(SSA) antibody in rheumatoid arthritis. J Rheumatol. 15:1988;391-394
15. Ben-Chetrit E., Fox R.I., Tan E.M. Dissociation of immune responses to the SS-A(Ro) 52kDa and 60kDa polypeptides in systemic lupus erythematosus and Goujerot-Sjögren's syndrome. Arthritis Rheum. 33:1990;49-55
16. Slobbe R.L., Pruijn G.J.M., Damen W.G.M., Van Der Kemp J.W.C.M., Van Venrooij W.J. Detection and occurrence of the 60 and 52kDa Ro(SSA) antigens and autoantibodies against these proteins. Clin Exp Immunol. 86:1991;99-105
17. Tsuzaka K., Fujii T., Akizuki M., Mimori T., Tojo T., Fujii H., et al. Clinical significance of antibodies to native or denatured 60 or 52kDa Ro/SSA proteins in Goujerot-Sjögren's syndrome. Arthritis Rheum. 37:1994;88-92
18. Saint Clair E.W., Burch J.A., Saitta M. Specificity of autoantibodies for recombinant 60 and 52kDa Ro autoantigens. Arthritis Rheum. 37:1994;1373-1379
19. Lopez-Longo F.J., Rodriguez-Mahou M., Escalona M., Perez T., Monteagudo I., Sanchez-Atrio A., et al. Heterogeneity of the anti-Ro(SSA) response in rheumatic diseases. J Rheumatol. 21:1994;1450-1456
20. Bozic B., Pruijn G.J.M., Rozman B., Van Venrooij W.J. Sera from patients with Rheumatic diseases recognize different epitope regions on the 52kDa Ro/SSA protein. Clin Exp Immunol. 94:1993;227-235
21. Belfiore N., Rossi S., Bobbio-Pallavicini F., Epis O., Caporali R., Montecucco C. Anti-Ro(SSA) 52 and 60kDa specificities in undifferentiated connective tissue disease. Joint Bone Spine. 67:2000;183-187
22. Slobbe R.L., Pruijn G.J.M., Van Venrooij W.J. Ro(SS-A) and La(SS-B) ribonucleoprotein complexes: structure, function and antigenicity. Ann Med Interne. 142:1991;592-600
23. Keech C.L., Gordon T.P., Mccluskey J. Structural differencies between the human and mouse 52kDa Ro autoantigens associated with poorly conserved autoantibodiey activity across species. Clin Exp Immunol. 104:1996;255-263
24. Reichlin M., Rader M., Harley J.B. Autoimmune response to the Ro/SSA particle is directed to the human antigen. Clin Exp Immunol. 76:1989;373-377
25. Ricchiuti V., Briand J.P., Meyer O., Isenberg D.A., Pruijn G.J.M., Muller S. Epitope mapping with synthetic peptides of 52kDa SSA/Ro protein reveals heterogeneous antibody profiles in human autoimmune sera. Clin Exp Immunol. 95:1994;397-407
26. McCauliffe D.P., Wang L., Satoh M., Reeves W., Small D. Recombinant 52kDa Ro(SSA) Elisa detects autoantibodies in Goujerot-Sjögren's syndrome sera that go undetected by conventionnal serologic assays. J Rheumatol. 24:1997;860-866
27. Manns M.P., Strassburg C.P. Autoimmune hepatitis: clinical challenges. Gastroenterology. 120:2001;1502-1517
28. Vogel W., Penner E. Heterogeneity of antinuclear antibodies in autoimmune liver diseases. Autoimmune liver diseases. 1991;Raven Press, New-York
29. Gregorio G.V., Davies E.T., Mieli-Vergani G., Vergani D. Significance of extractable nuclear antigens in childhood autoimmune liver disease. Clin Exp Immunol. 102:1995;308-313
30. Czaja A.J., Nishioka M., Morshed S.A., Hashiya T. Patterns of nuclear immunofluorescence and reactivities to recombinant nuclear antigens in autoimmune hepatitis. Gastroenterology. 107:1994;200-207
31. Li L., Chen M., Huang D.Y., Nishioka M. Frequency and significance of antibodies to chromatin in autoimmune hepatitis type I. J Gastroenterol Hepatol. 15:2000;1176-1182
32. D'amico E., Palazzi C., Cacciatore P., Canelli A., Ursitti G., Cosentino L., et al. Anti-ENA antibodies in patients with chronic hepatitis C virus infection. Dig Dis Sci. 47:2002;755-759
33. Muratori P., Muratori L., Stroffolini T., Pappas G., Terlizzi P., Ferrari R., et al. Prevalence of non-organ specific autoantibodies in HCV-infected subjects in the general population. Clin Exp Immunol. 131:2003;118-121
34. Strassburg C.P., Obermayer-Straub P., Manns P. Autoimmunity in hepatitis C and D virus infection. J Viral Hepatitis. 3:1996;49-59
35. Covini G., Von Muhlen C.A., Pachetti S., Colombo M., Chan E.K.L., Tan E.M. Diversity of antinuclear antibody responses in hepatocellular carcinoma. J Hepatol. 26:1997;1255-1265
36. Tomer Y., Sherer Y., Shoenfeld Y. Autoantibodies, autoimmunity and cancer. Oncol Reports. 1995;753-761
37. Imai H., Nakano Y., Kiyosawa K., Tan E.M. Increasing titers and changing specificities of antinuclear antibodies in patients with chronic liver disease who develop hepatocellular carcinoma. Cancer. 71:1993;26-35
38. Wasserman J., Glas U., Blomgren H. Autoantibodies in patients with carcinoma of the breast. Clin Exp Imunol. 19:1975;417-422
39. Thomas P.J., Kaur J.S., Aitcheson C.T., Robinson W.A., Tan E.M. Antinuclear, antinucleolar, and anticytoplasmic antibodies in patients with malignant melanoma. Cancer Res. 43:1983;1372-1380
40. Imai H., Ochs R.L., Kiyosawa, Furuta S., Nakamura R.M., Tan E.M. Nucleolar antigens and autoantibodies in hepatocellular carcinoma and other malignancies. Am J Pathol. 140:1992;859-870
41. Brenard R. Practical management of patients treated with alpha interferon. Acta Gastroenterol Belg. 60:1997;211-213
42. Pouthier D., Theissen F., Humbel R.L. Lupus syndrome, hypothyroïdism and bullous skin lesions after interferon alpha therapy for hepatitis C in a hemodialysis patient. Nephrol Dial Transplant. 17:2002;174
43. Wandl U.B., Nagel-Hiemke M., May D., Kreuzfelder E., Kloke O., Kranzhoff M., et al. Lupus-like auto-immune disease induced by interferon therapy for myeloproliferative disorders. Clin Immunol Immunopathol. 65:1992;70-74
44. Papo T. Interféron alpha et auto-immunité Méd Ther. 1:2000;66-74
45. Flores A., Olive A., Feliu E., Tena X. Systemic lupus erythematosus following interferon therapy. Br J Rheumatol. 33:1994;787
46. Srivastava M., Rencic A., Diglio G., Santana H., Bonitz P., Watson R., et al. Drug-induced, Ro/SSA-positive cutaneous lupus erythematosus. Arch Dermatol. 139:2003;45-49
47. Leone J., Pennaforte J.L., Hamon R., Cleenewerck N., Vallerand H., Detree F., et al. Manifestations pulmonaires du syndrome de Gougerot-Sjögren primitif. À propos de huit observations dans une série de 35 patients. Rev Med Interne. 17:1997;291-299
48. Matteson E.L., Ike R.W. Bronchiolis obliterans organizing pneumonia and Gougerot-Sjögren's syndrome. J Rheumatol. 17:1990;676-679
49. Lambert M., Hebbar M., Viget N., Hatron P.Y., Hachulla E., Devulder B. Bronchiolite oblitérante avec pneumopathie organisée: une complication rare du syndrome de Gougerot-Sjögren primitif. Rev Med Interne. 21:2000;74-77
50. Kaplan G., Mariette X. Kahn M.F., et al. Maladies et syndromes systémiques. Syndrome de Gougerot-Sjögren. 2000;533-573 Flammarion Médecine Science, Paris
51. Pourmand N., Blomberg S., Ronnblom L., Karlsson-Parra A., Petersson I., Wahren-Herlenius M. Ro 52kDa autoantibodies are detected in a subset of ANA-negative sera. Scand J Rheumatol. 29:2000;116-123
52. Franck M.B., Mccubbin V., Trieu E.W.U.Y., Isenberg D.A., Targoff I. The association of anti-Ro52 autoantibodies with myositis and scleroderma autoantibodies. J Autoimmun. 12:1999;137-142
53. Fujimoto M., Shimozuma M., Yazawa N., Kubo M., Ihn H., Sato S., et al. Prevalence and clinical relevance of 52 and 60kDa Ro/SSA autoantibodies in Japanese patients with systemic sclerosis. Ann Rheum Dis. 56:1997;667-670
54. Peene I., Meheus L., De Keyser S., Humbel R., Veys E.M., De Keyser F. Anti-Ro52 reactivity is an independent and additional serum marker in connective tissue disease. Ann Rheum Dis. 61:2002;929-933
55. Humbel R.L., Schmit P., Liedvogel B., Stahnke G., Goetz J., Sibilia J., et al. Evaluation of the clinical significance of antibodies directed against SSA/Ro52 and SSA/Ro60 antigens. Clin Exp Rheumatol. 12:(Suppl 11):1994;S-98
56. Bunn C.C., Black C.M. Systemic sclerosis: an autoantibody mosaic. Clin Exp Immunol. 117:1999;207-208
57. Rutjes S.A., Vree Egberts W.T.M., Jongen P., Van Den Hoogen F., Pruijn G.J.M., Van Venrooij W.J. Anti-Ro52 antibodies frequently co-occur with Anti-JO1 antibodies in sera from patients with idiopathic inflammatory myopathy. Clin Exp Immunol. 109:1997;32-40
58. Venables P.J.W. Antibodies to JO1 and Ro52: why do they go together? Clin Exp Immunol. 109:1997;403-405
59. Gal I., Lakos G., Zeher M. Comparison of the Anti-Ro/SSA autoantibody profile between patients with primary and secondary Gougerot-Sjögren's syndrome. Autoimmunity. 32:2000;89-92
60. Mavragani C.P., Tzoufias A.G., Moutsopoulos H.M. Gougerot-Sjögren's syndrome: autoantibodies to cellular antigens. Int Arch Allergy Immunol. 123:2000;46-57
61. Meyer O. Actualités sur les anti-SSA/Ro et anti-SSB/La. Ann Méd Interne. 153:2002;520-529
62. Peene I., Meheus L., Veys E.M., De Keyser F. Diagnostic associations in a large and consecutively identified population positive for anti-SSA and/or anti-SSB: the range of associated diseases differs according to the detailed serotype. Ann Rheum Dis. 61:2002;1090-1094
63. Bouffard P., Laniel M.A., Boire G. Anti-Ro(SSA) antibodies: clinical significance and biological relevance. J Rheumatol. 23:1996;1838-1840
64. Rhodes D.A., Ihrke G., Reinicke A.T., Malcherek G., Towey M., Isenberg D.A., et al. The 52 000 MW Ro/SSA autoantigen in Gougerot-Sjögren's syndrome/Systemic lupus erythematosus (Ro52) is an interferon-γ inducible tripartite motif protein associated with membrane proximal structures. Immunology. 106:2002;246-256